Endoxifen, a new cornerstone of breast cancer therapy: Demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 6, 2010, Pages 814-817

  Ahmad, A ^a   Shahabuddin, S ^a   Sheikh, S ^a   Kale, P ^b   Krishnappa, M ^b   Rane, R C ^c   Ahmad, I ^a  

^a Jina Pharmaceuticals Inc   (United States)

^b Lambda Therapeut Research Pvt Ltd   (India)

^c Intas Pharmaceuticals Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOXIFEN CITRATE; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; TAMOXIFEN;

EID: 78449288139     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.196     Document Type: Article

References (19)

1. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388 (1998).
2. Johnson, M.D. et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159 (2004).
3. Lazarus, P., Blevins-Primeau, A.S., Zheng, Y. & Sun, d. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann. NY Acad. Sci. 1155, 99-111 (2009).
4. Daniel, P., Gaskell, S.J., Bishop, H., Campbell, c. & Nicholson, R.I. determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur. J. Cancer Clin. Oncol. 17, 1183-1189 (1981).
5. Borges, S. et al. Quantitative effect of cYP2d6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74 (2006).
6. Wu, X., Hawse, J.R., Subramaniam, M., Goetz, M.P., Ingle, J.N. & Spelsberg, T.c. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 69, 1722-1727 (2009).
7. Gjerde, J. et al. effects of cYP2d6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19, 56-61 (2008).
8. Sun, D. et al. Glucuronidation of active tamoxifen metabolites by the human UdP glucuronosyltransferases. Drug Metab. Dispos. 35, 2006-2014 (2007).
9. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot fashes. J. Clin. Oncol. 23, 9312-9318 (2005).
10. Kiyotani, K. et al. Signifcant effect of polymorphisms in cYP2d6 and ABcc2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28, 1287-1293 (2010).
11. Goetz, M.P. et al. The impact of cytochrome P450 2d6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
12. Kiyotani, K. et al. Impact of cYP2d6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99, 995-999 (2008).
13. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient cYP2d6 and cYP2c19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007).
14. Xu, Y. et al. Association between cYP2d6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19, 1423-1429 (2008).
15. Ferraldeschi, R. & Newman, W.G. The impact of cYP2d6 genotyping on tamoxifen treatment. Pharmaceuticals 3, 1122-1138 (2010).
16. Kelly, C.M. et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, c693 (2010).
17. Ahmad, A., Ali, S.M., Ahmad, M.U., Sheikh, S. & Ahmad, I. Orally administered Endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res. Treat. 122, 579-584 (2010).
18. Ali, S.M., Ahmad, A., Shahabuddin, S., Ahmad, M.U., Sheikh, S. & Ahmad, I. Endoxifen is a new potent inhibitor of PKc: a potential therapeutic agent for bipolar disorder. Bioorg. Med. Chem. Lett. 20, 2665-2667 (2010).
19. Rowland, M. & Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications 3rd edn. 87 (Lea & Febiger, Philadelphia, PA, 1994).